0001193125-16-446076.txt : 20160201 0001193125-16-446076.hdr.sgml : 20160201 20160201162101 ACCESSION NUMBER: 0001193125-16-446076 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160201 FILED AS OF DATE: 20160201 DATE AS OF CHANGE: 20160201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vascular Biogenics Ltd. CENTRAL INDEX KEY: 0001603207 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36581 FILM NUMBER: 161377520 BUSINESS ADDRESS: STREET 1: 6 JONATHAN NETANYAHU ST. CITY: OR YEHUDA STATE: L3 ZIP: 60376 BUSINESS PHONE: 972-3-6346450 MAIL ADDRESS: STREET 1: 6 JONATHAN NETANYAHU ST. CITY: OR YEHUDA STATE: L3 ZIP: 60376 6-K 1 d131462d6k.htm FORM 6-K Form 6-K

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of February 2016

Commission File Number: 001-36581

 

 

Vascular Biogenics Ltd.

(Translation of registrant’s name into English)

 

 

6 Jonathan Netanyahu St.

Or Yehuda

Israel 60376

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x                Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨                 No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

CONTENTS

On January 31, 2016, Professor Jacob George notified Vascular Biogenics Ltd. (the “Company”) of his resignation from the role of the Company’s Chief Scientific Officer, effective immediately, for personal reasons which are unrelated to the Company, its operations, policies or practices.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    VASCULAR BIOGENICS LTD.
Date: February 1, 2016     By:   /s/ Dror Harats
    Name:   Dror Harats
    Title:   Chief Executive Officer